Quantcast
Home > Quotes > VICL
VICL

Vical Incorporated Common Stock (VICL) Quote & Summary Data

$1.3
*  
0.08
6.56%
Get VICL Alerts
*Delayed - data as of Jun. 19, 2018  -  Find a broker to begin trading VICL now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    VICL Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
3.5
Today's High / Low
$ 1.3323 / $ 1.21
Share Volume
465,342
50 Day Avg. Daily Volume
217,459
Previous Close
$ 1.22
52 Week High / Low
$ 3.70 / $ 1.02
Market Cap
28,359,848
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.23

Intraday Chart

Shares Traded

Share Volume:
465,342
50 Day Avg. Daily Volume:
217,459

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.07

Trading Range

The current last sale of $1.30 is 27.45% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.3323 $ 3.70
 Low: $ 1.21 $ 1.02

Company Description (as filed with the SEC)

We research and develop biopharmaceutical products, including those based on our patented DNA delivery technologies, for the prevention and treatment of serious or life-threatening diseases. We currently have three active development programs in the area of infectious disease comprised of: * An ongoing Phase 2 trial of our HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection. The vaccine candidate is currently being evaluated in a Phase 2 study in adult subjects, 18 to 50 years of age who are randomized 2:1 to receive either vaccine or placebo. Recruitment of 261 subjects at 15 U.S. clinical sites was completed in April 2017 and dosing was completed in July 2017.  ... More ...  

Risk Grade

Where does VICL fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.21
Open Date:
Jun. 19, 2018
Close Price:
$ 1.22
Close Date:
Jun. 19, 2018

Consensus Recommendation

Analyst Info